The proprietary solid hard shell capsules for the treatment of chronic pain are scheduled for release in the first half of 2019.
The capsules will initially target a market that is estimated to be 1.9 million Australians who suffer chronic neuropathic pain.
Sufferers can access the treatment through the TGA’s special access scheme (SAS).
AusCann’s managing director Elaine Darby said: “AusCann elected to work with PCI Pharma due to their significant experience in providing manufacturing services of solid dose potent products to high standards of safety and quality.
“This allows AusCann to bring its first hard shell capsules into the chronic pain market as quickly as possible, while continuing to focus on the development of our second generation cannabinoid pharmaceutical products.”
Western Australia site proposed in early 2019
The manufacturing work by PCI Pharma complements AusCann’s research and development site it proposes to establish in Western Australia in early 2019.
The site will be focused on the development of AusCann’s cannabinoid pharmaceutical product pipeline.
It will encompass cultivation, extraction, new product development and manufacturing activities.
3.2 million Australians suffer chronic pain
Around 3.2 million Australians suffer chronic pain and existing treatments are lacking in efficacy and have notable side effects.
The main reason for the use of medicinal cannabis global is for the treatment of chronic pain.
Notably, it is also an area where there is clinical data supporting its use.